About: http://data.cimple.eu/news-article/e11df238afae9c5550dcff1f7db686a448a2d053698b648996ca816a

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/e11df238afae9c5550dcff1f7db686a448a2d053698b648996ca816a Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	People with cancer are more than twice as likely to die from COVID-19 than those without it, a large study published Thursday found. The data on more than 900 patients in the US, Canada and Spain which appeared in a paper in The Lancet, found that mortality increased the further the cancer had progressed. Cancer patients with decreased ability to carry out daily life tasks were more at risk than those with higher functionality. The paper's authors looked at how many people died within 30 days of being diagnosed of COVID-19 of all causes. "The 30-day all-cause mortality was 13 percent, more than twice the mortality reported as the global average by Johns Hopkins," Toni Choueiri, an oncologist at the Dana-Farber Cancer Institute who co-authored the paper told AFP. In keeping with previous studies, the team also found that advanced age, male sex, the presence of two or more underlying conditions, and former smoking status were all also tied to increased risk of death. But the receipt of chemotherapy or other anti-cancer therapies within four weeks of COVID-19 diagnosis did not affect mortality outcomes. "Taken together, these results suggest that fit patients with cancer and few comorbidities can and should proceed with appropriate anti-cancer treatment," said Choueiri. But those who have poor daily life functionality or a cancer which is progressing "need to have thoughtful conversations with their oncology providers about risk versus benefit of anti-cancer treatment," he added. Bill Cance, chief medical and scientific officer for the American Cancer Society which provided funding for the study, said: "This is a very high impact paper that shows how cancer patients are at higher risk for Covid." He added that the paper suggested that the drug combination of hydroxychloroquine and azithromycin may cause a three-fold greater risk of death -- an area that needed further exploration. The authors of the paper themselves said they could not draw a conclusion on this trend because it may have arisen from other factors. ia/ch
schema:headline	Cancer patients twice as likely to die from COVID-19: study
schema:mentions	American Cancer Society Johns Hopkins Hospital Oncology Azithromycin Comorbidity Tobacco smoking 30 Days (TV series) Chemotherapy The Lancet Mortality rate Ia (cuneiform) Hydroxychloroquine Spain Canada Cancer Coronavirus disease Severe acute respiratory syndrome coronavirus 2 Dana–Farber Cancer Institute Progressed (EP) Alpha-fetoprotein
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-05-28 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	positive sentiment
http://data.cimple...readability_score	82 (xsd:integer)
http://data.cimple...tology#hasEmotion	fear

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software